164 related articles for article (PubMed ID: 31691036)
1. Combination of L1 methylation and tumor-infiltrating lymphocytes as prognostic marker in advanced gastric cancer.
Kim Y; Rhee YY; Wen X; Cho NY; Bae JM; Kim WH; Kang GH
Gastric Cancer; 2020 May; 23(3):464-472. PubMed ID: 31691036
[TBL] [Abstract][Full Text] [Related]
2. Combinatory low methylation statuses of SAT-α and L1 are associated with shortened survival time in patients with advanced gastric cancer.
Kim Y; Wen X; Jeong S; Cho NY; Kim WH; Kang GH
Gastric Cancer; 2019 Jan; 22(1):37-47. PubMed ID: 29926315
[TBL] [Abstract][Full Text] [Related]
3. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
Won KY; Kim GY; Kim HK; Song MJ; Choi SI; Bae GE; Lim SJ
Pathol Res Pract; 2019 Nov; 215(11):152639. PubMed ID: 31582185
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications and interaction of L1 methylation and p53 expression statuses in advanced gastric cancer.
Shin YJ; Kim Y; Wen X; Cho NY; Lee S; Kim WH; Kang GH
Clin Epigenetics; 2019 May; 11(1):77. PubMed ID: 31088544
[TBL] [Abstract][Full Text] [Related]
5. Methylation statuses of NCOR2, PARK2, and ZSCAN12 signify densities of tumor-infiltrating lymphocytes in gastric carcinoma.
Wen X; Jin HY; Li M; Kim Y; Cho NY; Kwak Y; Bae JM; Lee HS; Kang GH
Sci Rep; 2022 Jan; 12(1):862. PubMed ID: 35039565
[TBL] [Abstract][Full Text] [Related]
6. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
Chang H; Jung WY; Kang Y; Lee H; Kim A; Kim HK; Shin BK; Kim BH
Oncotarget; 2016 Dec; 7(49):80426-80434. PubMed ID: 27741514
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
[TBL] [Abstract][Full Text] [Related]
9. Methylation status of long interspersed element-1 in advanced gastric cancer and its prognostic implication.
Song YS; Kim Y; Cho NY; Yang HK; Kim WH; Kang GH
Gastric Cancer; 2016 Jan; 19(1):98-106. PubMed ID: 25609453
[TBL] [Abstract][Full Text] [Related]
10. Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas.
Heo YJ; Lee T; Byeon SJ; Kim EJ; Shin HC; Kim B; Kang SY; Ha SY; Kim KM
J Pathol Clin Res; 2021 Jan; 7(1):42-51. PubMed ID: 32885920
[TBL] [Abstract][Full Text] [Related]
11. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.
Lu J; Xu Y; Wu Y; Huang XY; Xie JW; Wang JB; Lin JX; Li P; Zheng CH; Huang AM; Huang CM
BMC Cancer; 2019 Sep; 19(1):920. PubMed ID: 31521128
[TBL] [Abstract][Full Text] [Related]
16. Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer.
Zhang D; He W; Wu C; Tan Y; He Y; Xu B; Chen L; Li Q; Jiang J
Front Immunol; 2019; 10():71. PubMed ID: 30761139
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer.
Hynes CF; Kwon DH; Vadlamudi C; Lofthus A; Iwamoto A; Chahine JJ; Desale S; Margolis M; Kallakury BV; Watson TJ; Haddad NG; Marshall MB
Ann Thorac Surg; 2018 Oct; 106(4):1002-1007. PubMed ID: 29859152
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
[TBL] [Abstract][Full Text] [Related]
19. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
20. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Noh BJ; Kwak JY; Eom DW
BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
